Inventor · disambiguated record
Jeffrey A. Ledbetter
Also filed as: LEDBETTER JEFFREY · LEDBETTER JEFFREY A · LEDBETTER JEFFREY ALAN
83 granted patents·48 pending applications·10,340 citations·filing 1984–2025
99Inventor score
Files withBRISTOL MYERS SQUIBB CO41LEDBETTER JEFFREY A10THERIPION INC10TRUBION PHARMACEUTICALS INC10UNIV WASHINGTON7
Top patents by PatentIndex Score
131 records- 0199US5977318ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Nov 2, 1999·438 cites·4 claims
- 0299US5500362AChimeric antibody with specificity to human B cell surface antigenXOMA CORP·Filed 1991·Granted Mar 19, 1996·2.8k cites·9 claims
- 0398US12180521B2Paraoxonase fusion polypeptides and related compositions and methodsTHERIPION INC·Filed 2022·Granted Dec 31, 2024·6 cites·22 claims
- 0498US7754208B2Binding domain-immunoglobulin fusion proteinsTRUBION PHARMACEUTICALS INC·Filed 2002·Granted Jul 13, 2010·111 cites·8 claims
- 0598US6623940B1Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cellBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Sep 23, 2003·133 cites·17 claims
- 0698US6132992AExpression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cellBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Oct 17, 2000·387 cites·54 claims
- 0798US5844095ACTLA4 Ig fusion proteinsBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Dec 1, 1998·417 cites·2 claims
- 0898US5721108AChimeric antibody with specificity to human B cell surface antigenXOMA CORP·Filed 1995·Granted Feb 24, 1998·269 cites·25 claims
- 0998US5677180AChimeric antibody with specificity to human B cell surface antigenXOMA CORP·Filed 1995·Granted Oct 14, 1997·316 cites·12 claims
- 1098US5637481AExpression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cellBRISTOL MYERS SQUIBB CO·Filed 1993·Granted Jun 10, 1997·331 cites·22 claims
- 1198US5434131AChimeric CTLA4 receptor and methods for its useBRISTOL MYERS SQUIBB CO·Filed 1993·Granted Jul 18, 1995·374 cites·8 claims
- 1297US11306297B2Therapeutic nuclease compositions and methodsUNIV WASHINGTON·Filed 2017·Granted Apr 19, 2022·7 cites·28 claims
- 1397US7118751B1DNA vaccines encoding antigen linked to a domain that binds CD40TRUBION PHARMACEUTICALS INC·Filed 2000·Granted Oct 10, 2006·92 cites·14 claims
- 1497US6893625B1Chimeric antibody with specificity to human B cell surface antigenROYALTY PHARMA FINANCE TRUST·Filed 2000·Granted May 17, 2005·159 cites·8 claims
- 1597US6652852B1Chimeric antibody with specificity to human B cell surface antigenROYALTY PHARMA FINANCE TRUST·Filed 2000·Granted Nov 25, 2003·144 cites·30 claims
- 1697US6010902AAntibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activityBRISTOL MEYERS SQUIBB CO·Filed 1994·Granted Jan 4, 2000·262 cites·28 claims
- 1797US5968510ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1996·Granted Oct 19, 1999·157 cites·1 claims
- 1897US5916560AMethods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewithBRISTOL MYERS SQUIBB CO·Filed 1997·Granted Jun 29, 1999·175 cites·24 claims
- 1997US5885796ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Mar 23, 1999·199 cites·12 claims
- 2097US5580756AB7Ig fusion proteinBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Dec 3, 1996·238 cites·3 claims
- 2197US5521288ACD28IG fusion proteinBRISTOL MYERS SQUIBB CO·Filed 1994·Granted May 28, 1996·233 cites·2 claims
- 2296US8841416B2Therapeutic nuclease compositions and methodsLEDBETTER JEFFREY A·Filed 2011·Granted Sep 23, 2014·34 cites·118 claims
- 2396US8147835B2Binding domain-immunoglobulin fusion proteinsLEDBETTER JEFFREY A·Filed 2009·Granted Apr 3, 2012·26 cites·22 claims
- 2496US7311910B2Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactionsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Dec 25, 2007·40 cites·9 claims
- 2596US6120767AChimeric antibody with specificity to human B cell surface antigenPHARMACEUTICAL ROYALTIES L L C·Filed 1998·Granted Sep 19, 2000·271 cites·15 claims
- 2696US5851795ASoluble CTLA4 molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Dec 22, 1998·182 cites·21 claims
- 2796US5773253AMYPPPY variants of CTL A4 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Jun 30, 1998·172 cites·17 claims
- 2896US5770197AMethods for regulating the immune response using B7 binding molecules and IL4-binding moleculesBRISTOL MYERS SQUIBB CO·Filed 1993·Granted Jun 23, 1998·200 cites·11 claims
- 2995US9005612B2Binding domain-immunoglobulin fusion proteinsLEDBETTER JEFFREY A·Filed 2012·Granted Apr 14, 2015·20 cites·22 claims
- 3095US8937157B2Therapeutic nuclease compositions and methodsUNIV WASHINGTON·Filed 2014·Granted Jan 20, 2015·24 cites·39 claims
- 3195US8409577B2Single chain multivalent binding proteins with effector functionTHOMPSON PETER ARMSTRONG·Filed 2007·Granted Apr 2, 2013·140 cites·17 claims
- 3295US6090914ACTLA4/CD28Ig hybrid fusion proteins and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Jul 18, 2000·149 cites·7 claims
- 3395US5747037AAnti-GP39 antibodiesBRISTOL MYERS SQUIBB CO·Filed 1995·Granted May 5, 1998·97 cites·8 claims
- 3495US5709859AMixed specificity fusion proteinsBRISTOL MYERS SQUIBB CO·Filed 1991·Granted Jan 20, 1998·143 cites·22 claims
- 3594US10000745B2Therapeutic nuclease compositions and methodsUNIV WASHINGTON·Filed 2015·Granted Jun 19, 2018·12 cites·22 claims
- 3694US7105166B1Soluble CTLA4 mutant molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Sep 12, 2006·33 cites·12 claims
- 3794US6830937B1Method for generating and identifying antibodies directed against a B7BRISTOL MYERS SQUIBB CO·Filed 2000·Granted Dec 14, 2004·39 cites·5 claims
- 3894US6482919B2Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cellBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Nov 19, 2002·68 cites·6 claims
- 3994US5876718AMethods of inducing T cell non-responsiveness to transplanted tissues and of treating graft-versus-host-disease with anti-gp39 antibodiesDARTMOUTH COLLEGE·Filed 1998·Granted Mar 2, 1999·86 cites·8 claims
- 4093US12258596B2Polynucleotides encoding paraoxonase fusion polypeptidesTHERIPION INC·Filed 2024·Granted Mar 25, 2025·0 cites·24 claims
- 4193US8197810B2Binding domain-immunoglobulin fusion proteinsLEDBETTER JEFFREY A·Filed 2010·Granted Jun 12, 2012·18 cites·29 claims
- 4293US8106161B2Binding domain-immunoglobulin fusion proteinsLEDBETTER JEFFREY A·Filed 2005·Granted Jan 31, 2012·19 cites·23 claims
- 4393US7829084B2Binding constructs and methods for use thereofTRUBION PHARMACEUTICALS INC·Filed 2003·Granted Nov 9, 2010·49 cites·4 claims
- 4493US7754209B2Binding constructs and methods for use thereofTRUBION PHARMACEUTICALS·Filed 2003·Granted Jul 13, 2010·54 cites·6 claims
- 4593US6887471B1Method to inhibit T cell interactions with soluble B7BRISTOL MYERS SQUIBB CO·Filed 1999·Granted May 3, 2005·66 cites·5 claims
- 4693US5885579ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1997·Granted Mar 23, 1999·122 cites·11 claims
- 4792US9416188B2Molecules that bind CD180, compositions and methods of useTHE UNIV OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION·Filed 2016·Granted Aug 16, 2016·8 cites·7 claims
- 4892US5540926ASoluble and its use in B cell stimulationBRISTOL MYERS SQUIBB CO·Filed 1992·Granted Jul 30, 1996·96 cites·18 claims
- 4991US9790479B2Therapeutic nuclease compositions and methodsUNIV WASHINGTON·Filed 2014·Granted Oct 17, 2017·9 cites·84 claims
- 5091US7572772B2Soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Aug 11, 2009·10 cites·6 claims
Showing the top 50 of 131 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jeffrey A. Ledbetter files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →